PMID- 36897734
OWN - NLM
STAT- MEDLINE
DCOM- 20230314
LR  - 20230916
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 102
IP  - 10
DP  - 2023 Mar 10
TI  - Effect of ertugliflozin on renal function and cardiovascular outcomes in patients 
      with type 2 diabetes mellitus: A systematic review and meta-analysis.
PG  - e33198
LID - 10.1097/MD.0000000000033198 [doi]
LID - e33198
AB  - BACKGROUND: The global prevalence of type 2 diabetes mellitus (T2DM) is growing 
      yearly. The efficacy of ertugliflozin (ERT), a recently licensed anti-diabetic 
      drug, has been widely reported. However, additional evidence-based data is 
      required to ensure its safety. In particular, convincing evidence on the effects 
      of ERT on renal function and cardiovascular outcomes is needed. METHODS: We 
      searched PubMed, Cochrane Library, Embase, and Web of Science for randomized 
      placebo-controlled trials of ERT for T2DM published up to August 11, 2022. 
      Cardiovascular events here mainly refer to acute myocardial infarction and angina 
      pectoris (AP) (including stable AP and unstable AP). The estimated glomerular 
      filtration rate (eGFR) was used to measure renal function. The pooled results are 
      risk ratios (RRs) and 95% confidence intervals (CIs). Two participants worked 
      independently to extract data. RESULTS: We searched 1516 documents and filtered 
      the titles, abstracts, and full text, 45 papers were left. Seven trials met the 
      inclusion criteria and were ultimately included in the meta-analysis. The 
      meta-analysis found that ERT reduced eGFR by 0.60 mL.min-1.1.733 m-2 (95% CI: 
      -1.02--0.17, P = .006) in patients with T2DM when used for no more than 52 weeks 
      and these differences were statistically significant. Compared with placebo, ERT 
      did not increase the risk of acute myocardial infarction (RR 1.00, 95% CI: 
      0.83-1.20, P = .333) and AP (RR 0.85, 95% CI: 0.69-1.05, P = .497). However, the 
      fact that these differences were not statistically significant. CONCLUSION: This 
      meta-analysis shows that ERT reduces eGFR over time in people with T2DM but is 
      safe in the incidence of specific cardiovascular events.
CI  - Copyright (c) 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Cheng, Qian
AU  - Cheng Q
AUID- ORCID: 0000-0003-4012-8693
AD  - Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Zou, Shupeng
AU  - Zou S
FAU - Feng, Chengyang
AU  - Feng C
FAU - Xu, Chan
AU  - Xu C
FAU - Zhao, Yazheng
AU  - Zhao Y
FAU - Shi, Xuan
AU  - Shi X
FAU - Sun, Minghui
AU  - Sun M
AUID- ORCID: 0000-0002-1556-543
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Hypoglycemic Agents)
RN  - 6C282481IP (ertugliflozin)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Myocardial Infarction/drug therapy
MH  - Kidney/physiology
PMC - PMC9997778
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2023/03/11 06:00
MHDA- 2023/03/15 06:00
PMCR- 2023/03/10
CRDT- 2023/03/10 12:04
PHST- 2023/03/10 12:04 [entrez]
PHST- 2023/03/11 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
PHST- 2023/03/10 00:00 [pmc-release]
AID - 00005792-202303100-00069 [pii]
AID - 10.1097/MD.0000000000033198 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2023 Mar 10;102(10):e33198. doi: 
      10.1097/MD.0000000000033198.